upper respiratory tract infections, 2 urinary tract infection, 1 Herpes labia-
lis), while 3 patients manifested Herpes Zoster reactivation, 2 deep vein thrombosis (one with pulmonary embolism), 2 discontinued due to severe anemia and pancytopenia, and 2 developed self-limiting liver enzymes elevation.

Conclusion: In our real-world dataset, baricitinib is effective in reducing RA disease activity, after 12 weeks, being generally well-tolerated with few severe adverse events.

Disclosure of Interests: Giacomo Maria Guidelli: None declared, Elena Generali: None declared, Chiara Bazzani: None declared, Roberto Gorla: None declared, Garfalia Sakellarious: None declared, Massimiliano Limonta: None declared, Maria Sole Chimenti: None declared, Roberto Perricone: None declared, Edouardo Conticini: None declared, Bruno Fre-
diani: None declared, Nicola Boffini: None declared, Lorenzo Dagna Con-
sultant for: Prof Lorenzo Dagna received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celtrion, Novartis, Pfizer, Sanofi-Genzyme, and SOBI, Marta Riva: None declared, Maria Rosa Pozzi: None declared, Rosa Daniela Grembiale Consultant for: Abbvie, Amgen, Biogen, CMS, Celgene, Medac, UCB, Speakers bureau: Abbvie, Abilen, Amgen-Sigma, Amgen, CMS, Genzyme, Carlo Selmi Grant/research support from: Abbvie, Abbies, Janssen, MSD, Novartis, Pfizer Consultant for: Abbvie, Amgen-Sigma, Biogen, CMS, Celgene, Eli-Lilly, GSK, Janssen, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Sanofi-Genzyme, YCB, Speakers bureau: Abbvie, Amgen-Sigma, Biogen, CMS, Celgene, Eli-Lilly, GSK, Janssen, Merck Sharp and Dohme, Novartis, Pfizer, Roche, Sanofi-Genzyme, YCB

AB0444

BIOPOLYMER THERAPY AND RADIOSYNOVIOPTHESIS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS

Marej Szentesi1, Zoltán Nagy2, Zsolt Karoly Mangel1, Pál Géher1.
1Polyclinic of the Hospitalier Brothers of St. John of God, Rheumatology, Budapest, Hungary;
2Polyclinic of the Hospitalier Brothers of St. John of God, Budapest, Hungary

Background: The treatment of patients with rheumatoid arthritis (RA) has been spectacularly changed since the 1950’s. Introduction of the steriod compounds and their local application, the chemical and radionuclide syn-
ovoectomy, surgical synovecctomy, use of non steroid drugs, the basic treatment of biological or basic therapy are the most important steps. Introduction of the biological therapy has changed the quality of life for these patients.

Objectives: During biological therapy sometimes 1 or 2 joints could be affected by inflammation. In this cases always the question is how to solve the problem. Change of the biological or basic therapy, use surgic-
cal synovecctomy or radiosynovectomy (RSO)?

Methods: In our rheumatological department 2100 patients with RA and PA were treated with biological therapy between 2002 and 2015. In 100 patients we applied RSO because of the inflammation of the knee joint during biological therapy. We made a long term follow-up in 72 patients. All participants provided written informed consent.

62 participants inflammatory knee joint disease was diagnosed on the basis of the American College of Rheumatology. 55 of 62 patients with rheumatoid arthritis were seropositive, 7 seronegative. Steinbrocker func-
tional stage II was observed in 52, stage III in 10. 10 patients were pauciarthritis. Mean age of 13 male and 61 female patients was 51.4 years (range 24-79) years. In 38 patients the right knee, in 34 the left knee was treated by radiosynovectomy. Mean duration of disease was 7.3 years (range 0.5-25), of synovitis (6.3month (range 3-8) Mean number of punctions of the treated joint prior to radiosynovectomy was 4.2 per patient and of steroid administrations prior to radiosynovectomy 3.0. In 12 patients a systemic steroid therapy has been performed.

Results: During the study period, inflammation decreased. In the first two years excellent and good results were recorded in 82.2%. Two years after radiosynovorhesis 83.3% of patients did not need another punction. Before the knee inflammation patients were in complete remission which status has been achieved after RSO as well. DAS: 2.4±0.4

Conclusion:
1. RSO is an effective method to treat the inflammation of the knees.
2. The RSO performed during biological tehrapy is as effective as in the case of patients without biological therapy.
3. In case of a successful RSO there is no need for biological or basic therapy neither for surgical synovectomy.

4. However an intraarticular injection has a low risk for infection it is recommended to avoid the biological therapy during the RSO.

REFERENCES
[6] Fellinger K. and Schmid J.; Die lokale Behandlung der rheumatischen Er-
[9] Feldmann M., Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoim-

Disclosure of Interests: None declared

venous thrombotic events, opportunistic infection/active TB, malignancy, GI perforation, or death.

### Table 1. Efficacy measures in the Japanese subgroup at weeks 12 and 24.

<table>
<thead>
<tr>
<th></th>
<th>FILD 200 mg OD</th>
<th>FILD 100 mg OD</th>
<th>PBO QD (n=13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR20 (%)</td>
<td>83% (p=0.015)</td>
<td>53% (p=0.28)</td>
<td>31%</td>
</tr>
<tr>
<td>Week 12</td>
<td>92% (p=0.001)</td>
<td>60% (p=0.024)</td>
<td>15%</td>
</tr>
<tr>
<td>Week 24</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HAQ-DI (LSM CFB)</td>
<td>-0.55 (95% CI: -0.30 (CI: -0.53 - 0.09) (CI: -0.16, 0.35)</td>
<td>0.81</td>
<td>0.07</td>
</tr>
<tr>
<td>Week 12</td>
<td>0.29</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>DAS28(CRP)</td>
<td>&lt;3.2 (p=0.001)</td>
<td>0.47 (p=0.007)</td>
<td>0%</td>
</tr>
<tr>
<td>Week 12</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

LSM CFB, least square mean change from baseline. P-values are vs PBO.

### Conclusion:
In this phase 3 study in bDMARD-IR patients with active RA, treatment with FIL over a 24-week period was associated with significant improvements in signs and symptoms of RA, with a safety and efficacy profile in Japanese patients consistent with that in the global population. Thus, FIL may provide a novel treatment option for patients who continue to have active RA prior to biologic therapy.

### REFERENCES

### Disclosure of Interests:

### PAIN REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB MONOTHERAPY WITH OR WITHOUT PAIN MEDICATION: A POST HOC ANALYSIS OF POOLED DATA FROM PHASE 2, PHASE 3 AND PHASE 3B/4 STUDIES

Peter C. Taylor1, Mart van de Laar2, Jeffrey R. Curtis3, Valderilio F. Azevedo4, José Luis Rivas5, Palė Dah1, Lisy Wang, Noriko Ikun6, Harry Shi7, John Woolcott8, Salim Benkhallafa9, Juan Jose Gomez-Reino10, Maxime Dougdas11, Botnar Research Centre, University of Oxford, Oxford, United Kingdom; 12Medische Spectrum Twente, Enschede, Netherlands; 13University of Alabama at Birmingham, Birmingham, AL, United States of America; 14Universidade Federal do Parana, Curitiba, Brazil; 15Pfizer SLU, Madrid, Spain; 16Pfizer Inc, Ballerup, Denmark; 17Pfizer Inc, Groton, CT, United States of America; 18Pfizer Inc, New York, NY, United States of America; 19Pfizer Inc, Collegeville, PA, United States of America; 20Pfizer SAS, Paris, France; 21Hospital Clinico Universitario, Santiago de Compostela, Spain; 22Cochin Hospital, Paris, France.

### Background:
Tofacitinib is an oral JAK inhibitor for the treatment of RA. Pain is the most common symptom reported by patients (pts) with RA, thus reduction of pain is an important treatment goal.

### Objectives:
To evaluate the effect of tofacitinib monotherapy ± pain medication on pain in pts with RA.

### Methods:
This pooled post hoc analysis included pts who received tofacitinib 5 mg BID monotherapy (ie without csDMARDs) in Phase (P2) (NCT00550544), P3 (ORAL Solo; NCT00814307) and Ptb/4 (ORAL...